Publications en collaboration avec des chercheurs de Complejo Asistencial Universitario de Burgos (14)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

2023

  1. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  2. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2021

  1. Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

    Health and Quality of Life Outcomes, Vol. 19, Núm. 1

  2. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

    Pancreatology, Vol. 21, Núm. 1, pp. 215-223

2019

  1. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  2. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis

    Oncologist, Vol. 24, Núm. 8, pp. e687-e695

2018

  1. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience

    Future Oncology, Vol. 13, Núm. 7, pp. 615-624

  2. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

2015

  1. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

  2. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248